WIC
MBRX icon

Woodmont Investment Counsel’s Moleculin Biotech MBRX Stock Holding History

Woodmont Investment Counsel’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5
Closed -$10K – 195
2020
Q4 		$10K Buy
+5
New +$8.87K ﹤0.01% 180

Other funds holding MBRX

SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Woodmont Investment Counsel's MBRX Position: Q1 2021 in Review

Woodmont Investment Counsel sold out of Moleculin Biotech (MBRX) in Q1 2021, closing a stake of 5 shares — an estimated $10K sold.

Woodmont Investment Counsel first reported a position in MBRX in Q4 2020 and held it in 1 quarter. The position peaked at $10K in Q4 2020. 27 funds tracked by Wall St. Rank hold MBRX as of Q1 2021.

  • Woodmont Investment Counsel reported no remaining Moleculin Biotech position as of Q1 2021 after selling out during the quarter.
  • Woodmont Investment Counsel sold 5 Moleculin Biotech shares in Q1 2021, an estimated $10K.
  • Woodmont Investment Counsel first reported a position in Moleculin Biotech in Q4 2020 and held it in 1 quarter.
  • Woodmont Investment Counsel's Moleculin Biotech position peaked at $10K in Q4 2020.
  • 27 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2021.

Based on Woodmont Investment Counsel's 13F filing for Q1 2021, filed 17 May 2021.